Zacks Research Brokers Decrease Earnings Estimates for BMY

Bristol Myers Squibb Company (NYSE:BMY) – Zacks Research reduced their Q1 2027 EPS estimates for shares of Bristol Myers Squibb in a research report issued to clients and investors on Tuesday, January 20th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $1.33 for the quarter, down from their previous estimate of $1.36. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q4 2027 earnings at $1.45 EPS and FY2027 earnings at $5.90 EPS.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The company had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.75 billion. During the same quarter in the prior year, the company earned $1.80 EPS. The firm’s revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.

Other equities analysts have also issued research reports about the company. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Guggenheim reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Tuesday, December 23rd. Dbs Bank upgraded shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Wells Fargo & Company raised their target price on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Seven research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and a consensus target price of $56.86.

Bristol Myers Squibb Stock Up 0.4%

Shares of NYSE BMY opened at $54.42 on Wednesday. The firm has a fifty day simple moving average of $52.28 and a two-hundred day simple moving average of $48.29. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $63.33. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. The firm has a market capitalization of $110.78 billion, a PE ratio of 18.38, a price-to-earnings-growth ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.6%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 85.14%.

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds have recently modified their holdings of the company. Trifecta Capital Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb in the 2nd quarter valued at $25,000. Harbor Capital Advisors Inc. lifted its stake in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares in the last quarter. REAP Financial Group LLC boosted its holdings in shares of Bristol Myers Squibb by 202.8% during the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 428 shares during the last quarter. Finally, Beacon Financial Strategies CORP purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at about $38,000. 76.41% of the stock is currently owned by institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Strategic partnership with Microsoft to apply AI for earlier lung‑cancer detection — this could improve screening, expand diagnostic reach for oncology-related programs and strengthen BMY’s tech-enabled clinical capabilities. Bristol Myers partners with Microsoft for AI-driven lung cancer detection
• Positive Sentiment: UK adoption set for Opdivo in early lung cancer — label expansion and broader reimbursement could boost sales trajectory for a core oncology franchise. New Opdivo use in early lung cancer set for adoption in UK
• Positive Sentiment: UBS upgraded BMY to Buy, citing a skewed risk/reward — analyst upgrades can attract flows and support short‑term upside. Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS
• Positive Sentiment: Leerink expresses bullish view on BMY’s pipeline optionality for 2026 — favorable analyst commentary adds conviction around mid‑term growth from launches and trials. Leerink Bullish on Bristol-Myers Squibb
• Positive Sentiment: Scotiabank and other commentators highlight BMY as an appealing oncology investment, supporting analyst interest and potential buy‑side demand. Scotiabank Notes Bristol-Myers Squibb (BMY) as Appealing Investment
• Neutral Sentiment: Update on KarXT long‑term urological safety study — ongoing data readouts matter for the drug’s commercial potential, but outcomes remain uncertain until full results. KarXT Safety Study: What Long-Term Urological Data Could Mean
• Neutral Sentiment: Zacks issued small, mixed EPS tweaks (slight Q4 upside, modest Q1/FY downgrades) — analyst estimate noise that may not meaningfully change the stock’s trajectory. Zacks Research EPS estimate changes
• Neutral Sentiment: Mentions on TV and investor videos (CNBC, YouTube) include BMY as a trade/blue‑chip idea — media attention can raise intraday interest but is not a fundamental catalyst. Final Trade: BMY, IGV, SOXX, GEN, AMZN
• Negative Sentiment: A recent write‑up flagged a 3.0% pullback and suggested institutional holders might take action — selling by large holders or volatility around position trimming could pressure the stock short term. Recent 3.0% pullback coverage

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.